135 related articles for article (PubMed ID: 7742525)
1. Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection.
Lacerda JF; Göker E; Kheradpour A; Dennig D; Elisseyeff Y; Jagiello C; O'Reilly RJ; Bertino JR
Blood; 1995 May; 85(10):2675-9. PubMed ID: 7742525
[TBL] [Abstract][Full Text] [Related]
2. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells.
Romanini A; Li WW; Colofiore JR; Bertino JR
J Natl Cancer Inst; 1992 Jul; 84(13):1033-8. PubMed ID: 1376779
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
Miyachi H; Takemura Y; Kobayashi H; Ando Y
Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
[TBL] [Abstract][Full Text] [Related]
4. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.
Trippett T; Schlemmer S; Elisseyeff Y; Goker E; Wachter M; Steinherz P; Tan C; Berman E; Wright JE; Rosowsky A
Blood; 1992 Sep; 80(5):1158-62. PubMed ID: 1381235
[TBL] [Abstract][Full Text] [Related]
5. Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.
Asai S; Miyachi H; Kobayashi H; Takemura Y; Ando Y
Cancer Sci; 2003 Feb; 94(2):210-4. PubMed ID: 12708499
[TBL] [Abstract][Full Text] [Related]
6. High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection?
Hum M; Holcenberg JS; Tkaczewski I; Weaver JW; Wilson J; Kamen BA
Clin Cancer Res; 1998 Dec; 4(12):2981-4. PubMed ID: 9865909
[TBL] [Abstract][Full Text] [Related]
7. Biomodulation of 5-fluorouracil with antifolates.
Bertino JR
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
[TBL] [Abstract][Full Text] [Related]
8. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
Kobayashi H; Takemura Y; Ohnuma T
Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
[TBL] [Abstract][Full Text] [Related]
9. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
Conti JA; Kemeny N; Seiter K; Goker E; Tong W; André M; Ragusa K; Bertino JR
J Clin Oncol; 1994 Apr; 12(4):695-700. PubMed ID: 7512128
[TBL] [Abstract][Full Text] [Related]
10. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
11. Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-CEM cell lines sensitive and resistant to methotrexate.
Romanini A; Chou TC; Bertino JR
Adv Enzyme Regul; 1989; 28():323-33. PubMed ID: 2533849
[TBL] [Abstract][Full Text] [Related]
12. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance.
Jansen G; Westerhof GR; Kathmann I; Rademaker BC; Rijksen G; Schornagel JH
Cancer Res; 1989 May; 49(9):2455-9. PubMed ID: 2706633
[TBL] [Abstract][Full Text] [Related]
13. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
[TBL] [Abstract][Full Text] [Related]
14. Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line.
Dixon KH; Trepel JB; Eng SC; Cowan KH
Cancer Commun; 1991; 3(12):357-65. PubMed ID: 16296001
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of methotrexate and trimetrexate and its reversal by folinic acid in human leukemic CCRF-CEM cells with carrier-mediated and receptor-mediated folate uptake.
van der Veer LJ; Westerhof GR; Rijksen G; Schornagel JH; Jansen G
Leuk Res; 1989; 13(11):981-7. PubMed ID: 2532692
[TBL] [Abstract][Full Text] [Related]
16. A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717).
Takemura Y; Ohnuma T; Miyachi H; Sekiguchi S
J Cancer Res Clin Oncol; 1991; 117(6):519-25. PubMed ID: 1683871
[TBL] [Abstract][Full Text] [Related]
17. Trimetrexate in relapsed T-cell lymphoma with skin involvement.
Sarris AH; Phan A; Duvic M; Romaguera J; McLaughlin P; Mesina O; King K; Medeiros LJ; Rassidakis GZ; Samuels B; Cabanillas F
J Clin Oncol; 2002 Jun; 20(12):2876-80. PubMed ID: 12065565
[TBL] [Abstract][Full Text] [Related]
18. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance.
Jansen G; Mauritz R; Drori S; Sprecher H; Kathmann I; Bunni M; Priest DG; Noordhuis P; Schornagel JH; Pinedo HM; Peters GJ; Assaraf YG
J Biol Chem; 1998 Nov; 273(46):30189-98. PubMed ID: 9804775
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors.
Allay JA; Spencer HT; Wilkinson SL; Belt JA; Blakley RL; Sorrentino BP
Blood; 1997 Nov; 90(9):3546-54. PubMed ID: 9345038
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacologic rationale for high-dose methotrexate.
Jolivet J
NCI Monogr; 1987; (5):61-5. PubMed ID: 2448656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
